| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cancer-Related Problem/Condition | |||||
| Fatigue | |||||
| 2 | More general conditions related to this trial | ||||
| Signs and Symptoms | |||||
| 3 | Interventions listed in this trial | ||||
| methylphenidate hydrochloride | |||||
| quality-of-life assessment | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Methylphenidate | |||||
| 5 | More general drug interventions related to this trial | ||||
| Central Nervous System Agents | |||||
| Central Nervous System Stimulants | |||||
| Dopamine Agents | |||||
| Dopamine Uptake Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Neurotransmitter Uptake Inhibitors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Eastern Cooperative Oncology Group | |||||
| National Cancer Institute (NCI) | |||||
|
